A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19
NCT ID: NCT05387369
Last Updated: 2022-05-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2000 participants
OBSERVATIONAL
2022-03-21
2027-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Evaluation of Paxlovid for COVID-19: a Real-world Case-control Study
NCT05532852
A Registry Study of Patients Hospitalized With Confirmed COVID-19
NCT05792865
RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms
NCT05965726
A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.
NCT07261085
A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19
NCT05263908
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Paxlovid
Patients with COVID-19 who visit Huashan Hospital,Fudan University from 2022 to 2027 and receive Paxlovid therapy
Paxlovid
The study is a real-world study. According to the actual medical history of patients, the usage of paxlovid will be collected.
Routine therapy
Patients with COVID-19 who visit Huashan Hospital,Fudan University from 2022 to 2027 and receive routine therapy without paxlovid
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Paxlovid
The study is a real-world study. According to the actual medical history of patients, the usage of paxlovid will be collected.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants who have one or more mild or moderate COVID-19 symptoms.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Huashan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jiming Zhang
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Feng Sun, MD
Role: PRINCIPAL_INVESTIGATOR
Huashan Hospital affliatied to Fudan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huashan Hospital Affiliated to Fudan University
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY2022-552
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.